U.S. Nutraceuticals Market to Witness Significant Incremental Opportunities Generate During the COVID-19 Lockdown Phase
Nutraceuticals are obtained from food sources and are highly enriched by different nutrients that are beneficial to good health. These drugs provide added health benefits compared to most standard diets and are known to be non-specific treatments used to manage symptoms and prevent various diseases. They can be categorised as functional foods, medicinal foods, nutritional supplements and pharmaceuticals. Nutraceuticals are extremely versatile in nature as they are used in the different sectors, including such food & beverage, feed additives, pharmaceuticals and personal care. Nutraceuticals products are available in a range of ways, such as tablets and capsules, powders, liquids and solids/semi-solids.
The U.S. nutraceutical market is expected to hit approximately US$ 119.8 million by the end of 2027 in terms of revenue, increasing at CAGR by 5.3 per cent during the forecast years (2019-2027).
Market Trends
Growing consumption of fermented foods, such as yoghurt, is a trend in the U.S., especially among the health-conscious consumer, who is the main source of revenue for the U.S. nutraceutical industry. For example, in July 2016, General Mills, which the major yoghurt manufacturer Yoplait, announced plans to reformulate or change 60 per cent of the items it currently offers under its yoghurt range in order to better reflect consumer demand.
Many manufacturers are growing the manufacturing potential of nutraceutical products in the U.S. and this is expected to drive demand growth. For example, in October 2019, Algatechnologies, part of the Solabia Group, announced that it had tripled its production capacity for FucoVitalTM. The action follows a rise in demand from the market for dietary supplements. FucoVital was released in the USA in 2018.
For More Information, Click Here: https://www.globenewswire.com/news-release/2020/04/23/2021012/0/en/U-S-Nutraceuticals-Market-to-reach-US-119-8-Mn-by-2027-Says-CMI.html
Comments
Post a Comment